Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

As India grapples with a mounting obesity crisis — with over 250 million individuals affected and health costs projected to ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Based on SOUL findings, Novo Nordisk submitted a label extension ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound ...